{"id":"NCT01991795","sponsor":"AstraZeneca","briefTitle":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","officialTitle":"A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-10","primaryCompletion":"2019-01-25","completion":"2019-01-25","firstPosted":"2013-11-25","resultsPosted":"2020-03-18","lastUpdate":"2020-03-18"},"enrollment":19271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Ticagrelor 60 mg","otherNames":["Brilinta/Brilique"]},{"type":"DRUG","name":"Ticagrelor placebo","otherNames":[]}],"arms":[{"label":"Ticagrelor 60 mg","type":"EXPERIMENTAL"},{"label":"Ticagrelor placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.","primaryOutcome":{"measure":"Composite of Cardiovascular (CV) Death, MI or Stroke","timeFrame":"From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.","effectByArm":[{"arm":"Ticagrelor 60 mg","deltaMin":736,"sd":null},{"arm":"Ticagrelor Placebo","deltaMin":818,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0378"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1237,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Norway","Peru","Philippines","Poland","Puerto Rico","Romania","Russia","Saudi Arabia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["31475798","31484629","30788847","38658101","36270493","33558152","27160944"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D513BC00001&attachmentIdentifier=04c28e5e-3d5e-4b76-824f-220474f85319&fileName=D513BC00001_CSP_redacted.pdf&versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D513BC00001&attachmentIdentifier=40d0421c-d5ae-4781-a3f8-69e550dcfd03&fileName=D513BC00001_SAP_redacted.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3049,"n":9562},"commonTop":["Dyspnoea"]}}